AI Article Synopsis

  • In medical research, accurately estimating cure rates among different treatments and patient groups is crucial, but challenges arise due to sample size limitations and the complexity of subgroup comparisons.
  • Current regression models often rely on the assumption of proportional hazards for different subgroups, which can lead to biased estimates when this assumption is not valid.
  • A new flexible cure model is proposed that accommodates both proportional and non-proportional hazards, enhancing the accuracy of cure rate estimations for varying covariates, as demonstrated in a study on stage III soft tissue sarcoma.

Article Abstract

In medical research, it is often of great interest to have an accurate estimation of cure rates by different treatment options and for different patient groups. If the follow-up time is sufficiently long and the sample size is large, the proportion of cured patients will make the Kaplan-Meier estimator of survival function have a flat plateau at its tail, whose value indicates the overall cure rate. However, it may be difficult to estimate and compare the cure rates for all the subsets of interest in this way, due to the limit of sample sizes and curse of dimensionality. In the current literature, most regression models for estimating cure rates assume proportional hazards (PH) between different subgroups. It turns out that the estimation of cure rates for subgroups is highly sensitive to this assumption, so more flexible models are needed, especially when this PH assumption is clearly violated. We propose a new cure model to simultaneously incorporate both PH and non-PH scenarios for different covariates. We develop a stable and easily implementable iterative procedure for parameter estimation through maximization of the nonparametric likelihood function. The covariance matrix is estimated by adding perturbation weights to the estimation procedure. In simulation studies, the proposed method provides unbiased estimation for the regression coefficients, survival curves, and cure rates given covariates, while existing models are biased. Our model is applied to a study of stage III soft tissue sarcoma and provides trustworthy estimation of cure rates for different treatment and demographic groups.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9691595PMC
http://dx.doi.org/10.1002/sim.9588DOI Listing

Publication Analysis

Top Keywords

cure rates
24
estimation cure
12
cure model
8
soft tissue
8
tissue sarcoma
8
cure
8
rates treatment
8
estimation
6
rates
6
flexible-hazards cure
4

Similar Publications

Background: Allogeneic hematopoietic cell transplantation (allo-HCT) is a potential cure for many hematological malignancies. Historically, older adults were not considered eligible for allo-HCT due to increased toxicity and mortality concerns. This systematic review and meta-analysis aim to explore the outcomes of allo-HCT in patients aged 70 years or older.

View Article and Find Full Text PDF

Surgery for Obstructive Sleep Apnea in Children With Down Syndrome in an Australian Population.

Ann Otol Rhinol Laryngol

January 2025

School of Clinical Medicine, Women's Health Paediatrics and Child Health, University of New South Wales, Sydney, NSW, Australia.

Objectives: The prevalence of obstructive sleep apnea (OSA) is known to be higher in children with Down syndrome (DS) than the general pediatric population, with lower rates of surgical cure. This study aims to determine the prevalence and predictors of OSA and evaluate the outcomes of surgical intervention for OSA in a cohort of Australian children with DS.

Methodology: A retrospective chart review was conducted on 156 patients with DS from 0 to 18 years who had undergone overnight, attended polysomnography (PSG) at Sydney Children's Hospital from January 2010 to July 2023.

View Article and Find Full Text PDF

Objective: This study aimed to systematically evaluate the clinical efficacy of Jingjin (muscle region of the meridian, sinew/tendon/fascia) acupuncture therapy in treating peripheral facial paralysis.

Methods: A computerized search of PubMed, EMBASE, Cochrane Central Register of Controlled Clinical Studies, SCOPUS, Web of Science, PEDro, China Knowledge, Wanfang, and Wipu databases was performed for published randomized controlled trials (RCTs) on the treatment of peripheral facial paralysis using Jingjin acupuncture therapy from the beginning of the construction of the databases until 2 April 2024. After a two-person independent extraction of data, the studies were assessed for paper quality and then analyzed for meta-analysis using RevMan5.

View Article and Find Full Text PDF

Incidence of Inflammatory Bowel Disease in Canterbury, New Zealand, 2018-2023.

Dig Dis Sci

January 2025

Department of Medicine, University of Otago Christchurch, 2 Riccarton Avenue, PO Box 4345, Christchurch, 8140, New Zealand.

Background: New diagnoses of inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), can highlight health system burden and potentially give clues to disease aetiology. This population-based study aimed to measure the annual incidence of IBD over six years (2018-2023) in the Canterbury region of New Zealand.

Methods: The medical records from public and private gastroenterology clinics were examined for new patients with a confirmed diagnosis of IBD from 1 January 2018 to 31 December 2023.

View Article and Find Full Text PDF

Importance: The current standard-of-care salvage therapy in relapsed/refractory classic Hodgkin lymphoma (cHL) includes consolidation high-dose chemotherapy (HDCT)/autologous stem cell transplant (aSCT).

Objective: To investigate whether presalvage risk factors and fludeoxyglucose-18 (FDG) positron emission tomography (PET) response to reinduction chemotherapy can guide escalation or de-escalation between HDCT/aSCT or transplant-free consolidation with radiotherapy to minimize toxic effects while maintaining high cure rates.

Design, Setting, And Participants: EuroNet-PHL-R1 was a nonrandomized clinical trial that enrolled patients younger than 18 years with first relapsed/refractory cHL across 68 sites in 13 countries in Europe between January 2007 and January 2013.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!